MA27764A1 - Acides carboxyliques alpha-substitués servant de modulateurs de PPAR - Google Patents

Acides carboxyliques alpha-substitués servant de modulateurs de PPAR

Info

Publication number: MA27764A1
Authority: MA; Morocco
Prior art keywords: alpha; carboxylic acids; substituted carboxylic; formula; ppar
Prior art date: 2003-04-15

Application number

MA28552A

Other languages

English (en)

French (fr)

Inventor

Simon Bailey

Paul Stuart Humphries

Donald James Skalitzky

Wei-Guo Su

Luke Raymond Zehnder

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-15

Filing date

2005-10-14

Publication date

2006-02-01

2005-10-14 Application filed by Pfizer filed Critical Pfizer

2006-02-01 Publication of MA27764A1 publication Critical patent/MA27764A1/fr

Links

102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title abstract 4
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title abstract 4
150000001735 carboxylic acids Chemical class 0.000 title abstract 3
208000032928 Dyslipidaemia Diseases 0.000 abstract 1
208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/14—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Furan Compounds (AREA)
Pyridine Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA28552A 2003-04-15 2005-10-14 Acides carboxyliques alpha-substitués servant de modulateurs de PPAR MA27764A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US46321303P	2003-04-15	2003-04-15

Publications (1)

Publication Number	Publication Date
MA27764A1 true MA27764A1 (fr)	2006-02-01

Family

ID=33300053

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA28552A MA27764A1 (fr)	2003-04-15	2005-10-14	Acides carboxyliques alpha-substitués servant de modulateurs de PPAR

Country Status (25)

Country	Link
EP (1)	EP1615899A1 (is)
JP (1)	JP2006523671A (is)
KR (1)	KR20060009846A (is)
CN (1)	CN1805943A (is)
AP (1)	AP2005003418A0 (is)
AR (1)	AR044514A1 (is)
AU (1)	AU2004230316A1 (is)
BR (1)	BRPI0409429A (is)
CA (1)	CA2521915A1 (is)
CL (1)	CL2004000800A1 (is)
EA (1)	EA200501462A1 (is)
EC (1)	ECSP056105A (is)
IS (1)	IS8033A (is)
MA (1)	MA27764A1 (is)
MX (1)	MXPA05010967A (is)
NL (1)	NL1025946C2 (is)
NO (1)	NO20055370L (is)
OA (1)	OA13157A (is)
PA (1)	PA8600201A1 (is)
PE (1)	PE20050415A1 (is)
TN (1)	TNSN05262A1 (is)
TW (1)	TW200510353A (is)
UY (1)	UY28266A1 (is)
WO (1)	WO2004092145A1 (is)
ZA (1)	ZA200508362B (is)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005247473A1 (en) *	2004-05-25	2005-12-08	Metabolex, Inc.	Substituted triazoles as modulators of PPAR and methods of their preparation
NZ563866A (en)	2005-05-09	2011-03-31	Achillion Pharmaceuticals Inc	Thiazole compounds and methods of use
US8962825B2 (en)	2006-10-30	2015-02-24	Glaxosmithkline Intellectual Property Development Limited	Hydroxamates as inhibitors of histone deacetylase
AU2008221673B2 (en) *	2007-03-08	2013-03-28	Albireo Ab	2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
US8183263B2 (en)	2007-05-22	2012-05-22	Achillion Pharmaceuticals, Inc.	Heteroaryl substituted thiazoles
US8106209B2 (en)	2008-06-06	2012-01-31	Achillion Pharmaceuticals, Inc.	Substituted aminothiazole prodrugs of compounds with anti-HCV activity
WO2010009166A1 (en)	2008-07-14	2010-01-21	Gilead Colorado, Inc.	Oxindolyl inhibitor compounds
NZ602832A (en)	2008-07-14	2014-04-30	Gilead Sciences Inc	Fused heterocyclic hdac inhibitor compounds
JP5640005B2 (ja)	2008-07-14	2014-12-10	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｄａｃおよび／またはｃｄｋ阻害剤としてのイミダゾシルピリジン化合物
JP2011529504A (ja)	2008-07-28	2011-12-08	ギリアードサイエンシーズ，インコーポレイテッド	シクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物およびヘテロシクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物
KR20120031170A (ko)	2009-06-08	2012-03-30	길리애드 사이언시즈, 인코포레이티드	알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
WO2010144378A2 (en)	2009-06-08	2010-12-16	Gilead Colorado, Inc.	Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
DE102010055499A1 (de) *	2010-12-22	2011-06-16	W.C. Heraeus Gmbh	Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon
RU2014121984A (ru)	2011-10-31	2015-12-10	Ксенон Фармасьютикалз Инк.	Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
JP6014155B2 (ja)	2011-10-31	2016-10-25	ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃ．	ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
FR2982858B1 (fr) *	2011-11-18	2013-11-29	Rhodia Operations	Procede de fabrication de composes comprenant des fonctions nitriles
FR2984322B1 (fr) *	2011-12-16	2013-12-20	Rhodia Operations	Procede de fabrication de composes comprenant des fonctions nitriles
CN104718188B (zh)	2012-05-22	2018-08-21	基因泰克公司	N-取代的苯甲酰胺类及其在治疗疼痛中的用途
KR101663436B1 (ko)	2012-07-06	2016-10-06	제넨테크, 인크.	N-치환된 벤즈아미드 및 이의 사용 방법
RU2015143906A (ru)	2013-03-14	2017-04-18	Дженентек, Инк.	Замещенные триазолопиридины и способы их применения
BR112015023397A2 (pt)	2013-03-15	2017-07-18	Genentech Inc	benzoxazois substituídos e métodos de uso dos mesmos
WO2015078374A1 (en)	2013-11-27	2015-06-04	Genentech, Inc.	Substituted benzamides and methods of use thereof
JP2017525677A (ja)	2014-07-07	2017-09-07	ジェネンテック，インコーポレイテッド	治療用化合物及びその使用方法
HK1252567A1 (zh)	2015-05-22	2019-05-31	基因泰克公司	被取代的苯甲酰胺和其使用方法
JP2018526371A (ja)	2015-08-27	2018-09-13	ジェネンテック，インコーポレイテッド	治療化合物及びその使用方法
CA2999769A1 (en)	2015-09-28	2017-04-06	Genentech, Inc.	Therapeutic compounds and methods of use thereof
EP3380466A1 (en)	2015-11-25	2018-10-03	Genentech, Inc.	Substituted benzamides useful as sodium channel blockers
EP3436432B1 (en)	2016-03-30	2021-01-27	Genentech, Inc.	Substituted benzamides and methods of use thereof
PE20190980A1 (es)	2016-10-17	2019-07-09	Genentech Inc	Compuestos terapeuticos y metodos para utilizarlos
JP2020511511A (ja)	2017-03-24	2020-04-16	ジェネンテック，インコーポレイテッド	ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
AR114263A1 (es)	2018-02-26	2020-08-12	Genentech Inc	Compuestos terapéuticos y métodos para utilizarlos
US10947251B2 (en)	2018-03-30	2021-03-16	Genentech, Inc.	Therapeutic compounds and methods of use thereof
TW202003490A (zh)	2018-05-22	2020-01-16	瑞士商赫孚孟拉羅股份公司	治療性化合物及其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60007592T2 (de) *	1999-09-30	2004-09-16	Pfizer Products Inc., Groton	Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
WO2002064130A1 (en) *	2001-02-15	2002-08-22	Pfizer Products Inc.	Proliferative activator receptor (ppar) compounds

2004
- 2004-04-01 WO PCT/IB2004/001159 patent/WO2004092145A1/en not_active Ceased
- 2004-04-01 CA CA002521915A patent/CA2521915A1/en not_active Abandoned
- 2004-04-01 CN CNA2004800167362A patent/CN1805943A/zh active Pending
- 2004-04-01 EP EP04725121A patent/EP1615899A1/en not_active Withdrawn
- 2004-04-01 KR KR1020057019591A patent/KR20060009846A/ko not_active Ceased
- 2004-04-01 OA OA1200500283A patent/OA13157A/en unknown
- 2004-04-01 BR BRPI0409429-8A patent/BRPI0409429A/pt not_active IP Right Cessation
- 2004-04-01 AP AP2005003418A patent/AP2005003418A0/xx unknown
- 2004-04-01 JP JP2006506478A patent/JP2006523671A/ja active Pending
- 2004-04-01 MX MXPA05010967A patent/MXPA05010967A/es not_active Application Discontinuation
- 2004-04-01 AU AU2004230316A patent/AU2004230316A1/en not_active Abandoned
- 2004-04-01 EA EA200501462A patent/EA200501462A1/ru unknown
- 2004-04-12 PE PE2004000361A patent/PE20050415A1/es not_active Application Discontinuation
- 2004-04-13 AR ARP040101236A patent/AR044514A1/es unknown
- 2004-04-13 UY UY28266A patent/UY28266A1/es not_active Application Discontinuation
- 2004-04-14 TW TW093110410A patent/TW200510353A/zh unknown
- 2004-04-14 PA PA20048600201A patent/PA8600201A1/es unknown
- 2004-04-14 NL NL1025946A patent/NL1025946C2/nl not_active IP Right Cessation
- 2004-04-14 CL CL200400800A patent/CL2004000800A1/es unknown
2005
- 2005-09-15 IS IS8033A patent/IS8033A/is unknown
- 2005-10-14 ZA ZA200508362A patent/ZA200508362B/en unknown
- 2005-10-14 MA MA28552A patent/MA27764A1/fr unknown
- 2005-10-14 TN TNP2005000262A patent/TNSN05262A1/fr unknown
- 2005-10-14 EC EC2005006105A patent/ECSP056105A/es unknown
- 2005-11-14 NO NO20055370A patent/NO20055370L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
UY28266A1 (es)	2004-11-30
AP2005003418A0 (en)	2005-12-31
TNSN05262A1 (fr)	2007-07-10
AR044514A1 (es)	2005-09-14
BRPI0409429A (pt)	2006-04-18
OA13157A (en)	2006-12-13
NL1025946C2 (nl)	2005-02-01
AU2004230316A1 (en)	2004-10-28
CL2004000800A1 (es)	2005-03-04
CA2521915A1 (en)	2004-10-28
WO2004092145A8 (en)	2005-05-12
IS8033A (is)	2005-09-15
NO20055370D0 (no)	2005-11-14
MXPA05010967A (es)	2005-11-28
EP1615899A1 (en)	2006-01-18
PA8600201A1 (es)	2005-02-04
NO20055370L (no)	2006-01-12
NL1025946A1 (nl)	2004-10-18
WO2004092145A1 (en)	2004-10-28
TW200510353A (en)	2005-03-16
PE20050415A1 (es)	2005-06-13
CN1805943A (zh)	2006-07-19
ECSP056105A (es)	2006-03-01
JP2006523671A (ja)	2006-10-19
KR20060009846A (ko)	2006-02-01
EA200501462A1 (ru)	2006-04-28
ZA200508362B (en)	2006-11-29

Publication	Publication Date	Title
MA27764A1 (fr)	2006-02-01	Acides carboxyliques alpha-substitués servant de modulateurs de PPAR
MA31373B1 (fr)	2010-05-03	Composes amino-heterocycliques
MA27774A1 (fr)	2006-02-01	Inhibiteurs de phosphatidylinositol 3-kinase
MA58181B1 (fr)	2026-03-31	Composés tricycliques substitués
TNSN04156A1 (fr)	2007-03-12	Pyridinones substituees servant de modulateurs de la map-kinase p38
TNSN03130A1 (en)	2005-12-23	HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THEM, PHARMACEUTICAL USES THEREOF AND MATERIALS FOR THEIR SYNTHESIS
DE69920010D1 (de)	2004-10-14	Aromatische amin-derivate verwendbar als pharmazeutische mittel
MA28094A1 (fr)	2006-08-01	Dérivés [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine
MA27097A1 (fr)	2004-12-20	Aza-arylpiperazines
TNSN04164A1 (fr)	2007-03-12	Inhibiteurs de acc.
TN2009000204A1 (fr)	2010-10-18	Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
MA27908A1 (fr)	2006-05-02	Agents therapeutiques utiles pour le traitement de la douleur
TNSN04246A1 (fr)	2007-03-12	Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA29692B1 (fr)	2008-08-01	Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA30324B1 (fr)	2009-04-01	Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.
TNSN05104A1 (fr)	2007-05-14	Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA34361B1 (fr)	2013-07-03	Dérivés de tétrahydro-pyrido-pyrimidine
MA30532B1 (fr)	2009-06-01	Sulfonamides tricycliques condenses inhibiteurs de gamma-secretase
MA27775A1 (fr)	2006-02-01	Composes organiques
TN2011000252A1 (fr)	2012-12-17	Lactames servant d'inhibiteurs de beta-secretase
TNSN00232A1 (fr)	2005-11-10	Derives de 2,4-diaminopyrimidine nouveaux, et compositions les contenant
MA46229B1 (fr)	2020-10-28	Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA30916B1 (fr)	2009-11-02	Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
MA31742B1 (fr)	2010-10-01	Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
TNSN03140A1 (fr)	2005-12-23	Derives d'acides sulfoniques nouveaux.